Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX ) 5.270 +0.080 (+1.54%) Streaming Delayed Price Updated: 10:27 AM EST, Nov 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Amylyx Pharmaceuticals, Inc. - Common Stock < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm January 06, 2024 From Bragar Eagel & Squire Via GlobeNewswire 2 Biotech Stocks With Huge Catalysts in 2024 January 05, 2024 Important clinical-trial readouts on the way could send these stocks soaring in early 2024. Via The Motley Fool Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP) December 22, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire Earnings Preview For Amylyx Pharma November 08, 2023 Via Benzinga Expert Ratings for Amylyx Pharma August 11, 2023 Via Benzinga Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS December 04, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire These biotechs targeting multiple neurodegenerative diseases December 01, 2023 A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. Via MarketBeat Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 29, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire 3 Top-Rated Biotech Stocks That Analysts Are Loving Now November 28, 2023 Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies. Via InvestorPlace Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer November 28, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND November 27, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference November 21, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm November 15, 2023 From Bragar Eagel & Squire, P.C. Via Business Wire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Amylyx Pharmaceuticals, Inc. (AMLX) November 14, 2023 From Kirby McInerney LLP Via Business Wire Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session November 09, 2023 Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. Via Benzinga Amylyx Crashes 26% As New ALS Drug Faces A Barrage Of Troubles November 09, 2023 The company says patient discontinuations mounted in the quarter. Via Investor's Business Daily 12 Health Care Stocks Moving In Thursday's Pre-Market Session November 09, 2023 Via Benzinga Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results November 09, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023 November 02, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium October 19, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire 3 Under-the-Radar Biotech Stocks to Buy in 2023 October 19, 2023 These three lesser-known biotech companies are profitable and growing revenue. Via The Motley Fool 10 Health Care Stocks Whale Activity In Today's Session October 18, 2023 Via Benzinga Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process October 13, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire 2 Incredible Growth Stocks Near 52-Week Lows to Buy Now October 10, 2023 These two high-tech bio companies may be too cheap to ignore right now. Via The Motley Fool Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control October 10, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France October 05, 2023 From Amylyx Pharmaceuticals Via Business Wire RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting October 02, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences September 05, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire 3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List August 28, 2023 Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. Via InvestorPlace Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results August 10, 2023 From Amylyx Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
